Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1852608,
author = {Mlčoch, Tomáš and Bartáková, Jana and Chadimová, Kateřina and Ornstová, Eva and Decker, Barbora and Doležal, Tomáš},
booktitle = {ISPOR Europe 2019, Copenhagen},
doi = {http://dx.doi.org/10.1016/j.jval.2019.09.1435},
title = {Cost-effectiveness analysis of sucrose octasulfate (urgostart) dressing in the treatment of diabetic foot and venous leg ulcers},
url = {https://www.valueinhealthjournal.com/article/S1098-3015(19)33813-6/fulltext},
year = {2019}
}
TY - CONF
ID - 1852608
AU - Mlčoch, Tomáš - Bartáková, Jana - Chadimová, Kateřina - Ornstová, Eva - Decker, Barbora - Doležal, Tomáš
PY - 2019
TI - Cost-effectiveness analysis of sucrose octasulfate (urgostart) dressing in the treatment of diabetic foot and venous leg ulcers
UR - https://www.valueinhealthjournal.com/article/S1098-3015(19)33813-6/fulltext
N2 - From a health care payer perspective, SOD for NDFU and VLU were dominant. SOD brought 0.03 (0.67 vs. 0.64) and 0.05 (0.53 vs. 0.48) incremental QALY, respectively. Incremental costs were €-5 (€1,518 vs. €1,523) and €-143 (€925 vs. €783), respectively. Sensitivity analysis showed that even with the SOD price ten-time higher than CD, the incremental cost-effectiveness ratio stayed well below WTP threshold (€21,777 for NDFU and €2,888 for VLU).
ER -
MLČOCH, Tomáš, Jana BARTÁKOVÁ, Kateřina CHADIMOVÁ, Eva ORNSTOVÁ, Barbora DECKER a Tomáš DOLEŽAL. Cost-effectiveness analysis of sucrose octasulfate (urgostart) dressing in the treatment of diabetic foot and venous leg ulcers. In \textit{ISPOR Europe 2019, Copenhagen}. 2019. ISSN~1098-3015. Dostupné z: https://dx.doi.org/10.1016/j.jval.2019.09.1435.
|
